Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

NCT ID: NCT06280742

Last Updated: 2025-09-04

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2027-11-30

Brief Summary

The Service Hospitalier Frédéric-Joliot (SHFJ) and Paris Brain Institute (ICM) groups have identified [18F]-DPA-714 as a promising second-generation TSPO tracer, a macromolecule overexpressed in neuroinflammatory conditions, for PET imaging. They have also developed a non-invasive quantification methodology, enabling the generation of individual neuroinflammation maps in MS patients. Recent findings from [18F]-DPA-714 PET imaging in MS patients revealed that most of the white matter lesions contained a smoldering component, even when considered inactive on MRI, and that their neuroinflammatory profiles were associated with longitudinal disability worsening. The Inflanet project aims to leverage a unique consortium comprising French radiochemists, radiopharmacists, nuclear medicine/neuroimaging experts, and MS neurologists to establish the first national network dedicated to [18F]-DPA-714 PET imaging in MS, so far limited to monocentric studies.

The objectives of the INFLANET project are (1) to conduct the first multicenter study assessing neuroinflammation in patients with active MS using [18F]DPA-714 PET tracer, and (2) to establish a methodology suitable for the quantification of multicenter PET data obtained with [18F]DPA-714. The INFLANET initiative aims to disseminate TSPO PET within the French MS research community, thereby opening the unique perspective of future large-scale, multicenter studies. These endeavors are expected to enhance our capacity to predict diseases, stratify patients, and assess new therapeutic interventions.

Detailed Description

INFLANET is a multicentric, prospective, non-randomized, non-blinded, interventional study.The study will include a total of 41 participants, with 18 individuals diagnosed with multiple sclerosis (MS) distributed across three sites (6 patients per site: Paris, Lyon, Rennes). Additionally, there will be 23 healthy volunteers (HV), with 20 HV allocated to the Lyon and Rennes sites (10 HV per site) and 3 HV for the Paris site.

The study involves several clinical visits, with two visits for patients (Screening V0 and Baseline V1), two visits for 20 healthy volunteers (Screening V0 and Baseline V1), and three visits for three healthy volunteers (Screening V0, Baseline V1 - Test, and V1' - Retest, in Paris site). Various evaluations are integrated into the study, including neurological assessments at the screening visit, neuropsychological assessments at the baseline visit, 18F-DPA714 PET-MR or PET + MRI (n=1 for 20 HV and 18 subjetcs with MS; n=2 for 3 HV) at V1 and V1', and blood sampling at the screening visit to confirm TSPO eligibility.

The PET-MR procedure involves TSPO PET using [18F]-DPA-714 in conjunction with 3T MRI for both MS patients and healthy volunteers. Gadoteric acid is administered for MS patients only as part of the imaging.

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Patients

MRI with added injection of gadolinium

Group Type: EXPERIMENTAL

PET-MRI with [18F]-DPA-714

Intervention Type: RADIATION

PET-MRI with \[18F\]-DPA-714

Healthy Volunteers

Group Type: ACTIVE_COMPARATOR

PET-MRI with [18F]-DPA-714

Intervention Type: RADIATION

PET-MRI with \[18F\]-DPA-714

Interventions

PET-MRI with [18F]-DPA-714

PET-MRI with \[18F\]-DPA-714

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

RRMS patients:

• Age between 18 and 55 years old
• RRMS according to the 2017 Mc Donald criteria
• At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI
• Last treatment with methylprednisolone should have been performed at least 1 month before PET examinations
• No current disease modifying therapy
• Indication for a highly active disease modifying treatment: Natalizumab, anti CD20 antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will consist either as patients with an active form of relapsing MS or patients who have experienced two relapses during the previous year
• Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Healthy Volunteers:

• Age between 18 and 55 years old
• Without any evolutive pathology
• Able to understand the study objectives and procedures
• Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Exclusion Criteria

For all participants:

• Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace-maker or the presence of an intra-ocular foreign body, (a contra-indication questionnaire will be filled in beforehand)
• Realization of any test using radioactivity within the last 12 months
• Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit)
• Pregnancy, breast-feeding, lack of efficient contraception for women of childbearing potential
• Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases
• Unwillingness to be informed in case of unexpected MRI abnormality (with a significant medical anomaly)
• Patient under legal protection
• Participation in another interventional study or being in the exclusion period at the end of a previous study

RRMS patients:

• Hypersensitivity to gadoteric acid
• Meglumine or any drug containing gadolinium
• Severe renal insufficiency (creatinine clearance < 60mL/min and GFR <30ml / min / 1.73m2).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Département de Neurologie,Pierre Wertheimer Neurological Hospital

Lyon, , France

CERMEP

Lyon, , France

CIC Neurosciences, GH Pitié-Salpêtrière

Paris, , France

Centre Eugène Marquis

Rennes, , France

Service de Neurologie, CHU Pontchaillou

Rennes, , France

CHU Toulouse - Département de Neurologie

Toulouse, , France

CHU Toulouse - Service de médecine nucléaire

Toulouse, , France

Countries

France

Central Contacts

Bruno Stankoff, MD

Role: CONTACT

bruno.stankoff@aphp.fr

0171970659 ext. +33

Facility Contacts

Françoise DURAND-DUBIEF, MD

Role: primary

francoise.durand-dubief@chu-lyon.fr

04 72 35 75 22 ext. +33

Françoise DURAND-DUBIEF, MD

Role: primary

francoise.durand-dubief@chu-lyon.fr

04 72 35 75 22 ext. +33

Bruno Stankoff, MD

Role: primary

bruno.stankoff@aphp.fr

0171970659 ext. +33

Xavier Palard, MD

Role: primary

x.palard@rennes.unicancer.fr

02 99 25 30 83 ext. +33

Anne Kerbrat, MD

Role: primary

anne.kerbrat@chu-rennes.fr

02 99 28 42 94 ext. +33

Jonathan Ciron, Dr

Role: primary

ciron.j@chu-toulouse.fr

05 61 77 91 06 ext. +33

Pierre Payoux, Dr

Role: primary

Payoux.p@chu-toulouse.fr

06 80 14 42 25 ext. +33

Other Identifiers

APHP221366

Identifier Type: -

Identifier Source: org_study_id